Recently, we described a TR-FRET-based assay for the precise and objective quantitative analysis of HER family member expression in tumour cryosections.23 Here, we successfully applied this TR-FRET technology for the quantification of HER1, HER2 and HER3 in FFPE tumour samples. The gene discussed is ERBB2; the disease is neoplasm.